SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c. Following the live webcast, an archived version of the call will be available on the website.
Monday November 14 @ 4:30 pm ET | |
Domestic: | 1-877-407-0792 |
International: | 1-201-689-8263 |
Conference ID: | 13732765 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75%…
Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers.New…
NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem RALEIGH, N.C., June…
MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…
New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…
TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…